GrippeAllemagneV4, Main, Exploration, bibRecord, 000149

Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany.

Identifieur interne : 000149 ( Main/Exploration ); précédent : 000148; suivant : 000150

Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany.

Auteurs : Cornelius Remschmidt [Allemagne] ; Thorsten Rieck [Allemagne] ; Birte Bödeker [Allemagne] ; Ole Wichmann [Allemagne]

Source :

BMC infectious diseases [ 1471-2334 ] ; 2015.

RBID : pubmed:25887460

Descripteurs français

KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Allemagne (épidémiologie), Bases de données factuelles (MeSH), Dépistage de masse (méthodes), Femelle (MeSH), Grippe humaine (immunologie), Grippe humaine (prévention et contrôle), Grippe humaine (épidémiologie), Humains (MeSH), Jeune adulte (MeSH), Monitorage immunologique (méthodes), Mâle (MeSH), Résultat thérapeutique (MeSH), Saisons (MeSH), Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H3N2 du virus de la grippe A (immunologie), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Vaccination (méthodes), Vaccination (statistiques et données numériques), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (usage thérapeutique), Études cas-témoins (MeSH).
MESH :
- immunologie : Grippe humaine, Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Vaccins antigrippaux.
- méthodes : Dépistage de masse, Monitorage immunologique, Vaccination.
- prévention et contrôle : Grippe humaine.
- statistiques et données numériques : Vaccination.
- usage thérapeutique : Vaccins antigrippaux.
- épidémiologie : Allemagne, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Bases de données factuelles, Femelle, Humains, Jeune adulte, Mâle, Résultat thérapeutique, Saisons, Sujet âgé, Sujet âgé de 80 ans ou plus, Études cas-témoins.

English descriptors

KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Case-Control Studies (MeSH), Databases, Factual (MeSH), Female (MeSH), Germany (epidemiology), Humans (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H3N2 Subtype (immunology), Influenza Vaccines (immunology), Influenza Vaccines (therapeutic use), Influenza, Human (epidemiology), Influenza, Human (immunology), Influenza, Human (prevention & control), Male (MeSH), Mass Screening (methods), Middle Aged (MeSH), Monitoring, Immunologic (methods), Seasons (MeSH), Treatment Outcome (MeSH), Vaccination (methods), Vaccination (statistics & numerical data), Young Adult (MeSH).
MESH :
- chemical , immunology : Influenza Vaccines.
- epidemiology : Germany, Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza, Human.
- methods : Mass Screening, Monitoring, Immunologic, Vaccination.
- prevention & control : Influenza, Human.
- statistics & numerical data : Vaccination.
- chemical , therapeutic use : Influenza Vaccines.
- Adolescent, Adult, Aged, Aged, 80 and over, Case-Control Studies, Databases, Factual, Female, Humans, Male, Middle Aged, Seasons, Treatment Outcome, Young Adult.

Abstract

BACKGROUND

Elderly people are at increased risk for severe influenza illness and constitute therefore a major target-group for seasonal influenza vaccination in most industrialized countries. The aim of this study was to estimate influenza vaccine effectiveness (VE) among individuals aged 60+ years over three seasons and to assess if the screening method is a suitable tool to monitor influenza VE in this particular target-group in Germany.

METHODS

We identified laboratory-confirmed influenza cases aged 60+ years through the national communicable disease reporting system for seasons 2010/11, 2011/12 and 2012/13. Vaccination coverage (VC) data were retrieved from a database of health insurance claims representing ~85% of the total German population. We applied the screening method to calculate influenza subtype-specific VE and compared our results with VE estimates from other observational studies in Europe.

RESULTS

In total, 7,156 laboratory-confirmed influenza cases were included. VE against all influenza types ranged between 49% (95% confidence interval [CI]: 39-56) in 2011/12 and 80% (95% CI: 76-83%) in 2010/11. In 2010/11 subtype-specific VE against influenza A(H1N1)pdm and B was 76% and 84%, respectively. In the following seasons, VE against influenza A(H1N1)pdm, A(H3N2) and B was 87%, -9% , 74% (2011/12), and 74%, 39%, 73% (2012/13). VE was higher among hospitalized compared to non-hospitalized influenza A cases. Seventeen observational studies from Europe reporting subtype-specific VE among the elderly were identified for the respective seasons (all applying the test-negative design) and showed comparable subtype-specific VE estimates.

CONCLUSIONS

According to our study, influenza vaccination provided moderate protection against laboratory-confirmed influenza A(H1N1)pdm and B in individuals aged 60+ but no or only little protection against A(H3N2). Higher VE among hospitalized cases might indicate higher protection against severe influenza disease. Based on the available data, the screening method allowed us to assess subtype-specific VE in hospitalized and non-hospitalized elderly persons. Since controlling for several important confounders was not possible, the applied method only provided crude VE estimates. However, given the precise VC-data and the large number of cases, the screening method provided results being in line with VE estimates from other observational studies in Europe that applied a different study design.

DOI: 10.1186/s12879-015-0882-3
PubMed: 25887460
PubMed Central: PMC4371628

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000139
to stream Main, to step Curation: 000139

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany.</title>
<author><name sortKey="Remschmidt, Cornelius" sort="Remschmidt, Cornelius" uniqKey="Remschmidt C" first="Cornelius" last="Remschmidt">Cornelius Remschmidt</name>
<affiliation wicri:level="3"><nlm:affiliation>Immunization Unit, Robert Koch Institute, Berlin, Germany. Remschmidtc@rki.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Immunization Unit, Robert Koch Institute, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rieck, Thorsten" sort="Rieck, Thorsten" uniqKey="Rieck T" first="Thorsten" last="Rieck">Thorsten Rieck</name>
<affiliation wicri:level="3"><nlm:affiliation>Immunization Unit, Robert Koch Institute, Berlin, Germany. RieckT@rki.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Immunization Unit, Robert Koch Institute, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Charité - University Medicine Berlin, Berlin, Germany. RieckT@rki.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Charité - University Medicine Berlin, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bodeker, Birte" sort="Bodeker, Birte" uniqKey="Bodeker B" first="Birte" last="Bödeker">Birte Bödeker</name>
<affiliation wicri:level="3"><nlm:affiliation>Immunization Unit, Robert Koch Institute, Berlin, Germany. BoedekerB@rki.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Immunization Unit, Robert Koch Institute, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wichmann, Ole" sort="Wichmann, Ole" uniqKey="Wichmann O" first="Ole" last="Wichmann">Ole Wichmann</name>
<affiliation wicri:level="3"><nlm:affiliation>Immunization Unit, Robert Koch Institute, Berlin, Germany. WichmannO@rki.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Immunization Unit, Robert Koch Institute, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25887460</idno>
<idno type="pmid">25887460</idno>
<idno type="doi">10.1186/s12879-015-0882-3</idno>
<idno type="pmc">PMC4371628</idno>
<idno type="wicri:Area/Main/Corpus">000139</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000139</idno>
<idno type="wicri:Area/Main/Curation">000139</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000139</idno>
<idno type="wicri:Area/Main/Exploration">000139</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany.</title>
<author><name sortKey="Remschmidt, Cornelius" sort="Remschmidt, Cornelius" uniqKey="Remschmidt C" first="Cornelius" last="Remschmidt">Cornelius Remschmidt</name>
<affiliation wicri:level="3"><nlm:affiliation>Immunization Unit, Robert Koch Institute, Berlin, Germany. Remschmidtc@rki.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Immunization Unit, Robert Koch Institute, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rieck, Thorsten" sort="Rieck, Thorsten" uniqKey="Rieck T" first="Thorsten" last="Rieck">Thorsten Rieck</name>
<affiliation wicri:level="3"><nlm:affiliation>Immunization Unit, Robert Koch Institute, Berlin, Germany. RieckT@rki.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Immunization Unit, Robert Koch Institute, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Charité - University Medicine Berlin, Berlin, Germany. RieckT@rki.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Charité - University Medicine Berlin, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bodeker, Birte" sort="Bodeker, Birte" uniqKey="Bodeker B" first="Birte" last="Bödeker">Birte Bödeker</name>
<affiliation wicri:level="3"><nlm:affiliation>Immunization Unit, Robert Koch Institute, Berlin, Germany. BoedekerB@rki.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Immunization Unit, Robert Koch Institute, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wichmann, Ole" sort="Wichmann, Ole" uniqKey="Wichmann O" first="Ole" last="Wichmann">Ole Wichmann</name>
<affiliation wicri:level="3"><nlm:affiliation>Immunization Unit, Robert Koch Institute, Berlin, Germany. WichmannO@rki.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Immunization Unit, Robert Koch Institute, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">BMC infectious diseases</title>
<idno type="eISSN">1471-2334</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Case-Control Studies (MeSH)</term>
<term>Databases, Factual (MeSH)</term>
<term>Female (MeSH)</term>
<term>Germany (epidemiology)</term>
<term>Humans (MeSH)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza A Virus, H3N2 Subtype (immunology)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (therapeutic use)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (immunology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Male (MeSH)</term>
<term>Mass Screening (methods)</term>
<term>Middle Aged (MeSH)</term>
<term>Monitoring, Immunologic (methods)</term>
<term>Seasons (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Vaccination (methods)</term>
<term>Vaccination (statistics & numerical data)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Allemagne (épidémiologie)</term>
<term>Bases de données factuelles (MeSH)</term>
<term>Dépistage de masse (méthodes)</term>
<term>Femelle (MeSH)</term>
<term>Grippe humaine (immunologie)</term>
<term>Grippe humaine (prévention et contrôle)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains (MeSH)</term>
<term>Jeune adulte (MeSH)</term>
<term>Monitorage immunologique (méthodes)</term>
<term>Mâle (MeSH)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Saisons (MeSH)</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Sous-type H3N2 du virus de la grippe A (immunologie)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Vaccination (méthodes)</term>
<term>Vaccination (statistiques et données numériques)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (usage thérapeutique)</term>
<term>Études cas-témoins (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Germany</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Mass Screening</term>
<term>Monitoring, Immunologic</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Dépistage de masse</term>
<term>Monitorage immunologique</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Vaccination</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Case-Control Studies</term>
<term>Databases, Factual</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Seasons</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Bases de données factuelles</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Résultat thérapeutique</term>
<term>Saisons</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Études cas-témoins</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Elderly people are at increased risk for severe influenza illness and constitute therefore a major target-group for seasonal influenza vaccination in most industrialized countries. The aim of this study was to estimate influenza vaccine effectiveness (VE) among individuals aged 60+ years over three seasons and to assess if the screening method is a suitable tool to monitor influenza VE in this particular target-group in Germany.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>We identified laboratory-confirmed influenza cases aged 60+ years through the national communicable disease reporting system for seasons 2010/11, 2011/12 and 2012/13. Vaccination coverage (VC) data were retrieved from a database of health insurance claims representing ~85% of the total German population. We applied the screening method to calculate influenza subtype-specific VE and compared our results with VE estimates from other observational studies in Europe.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>In total, 7,156 laboratory-confirmed influenza cases were included. VE against all influenza types ranged between 49% (95% confidence interval [CI]: 39-56) in 2011/12 and 80% (95% CI: 76-83%) in 2010/11. In 2010/11 subtype-specific VE against influenza A(H1N1)pdm and B was 76% and 84%, respectively. In the following seasons, VE against influenza A(H1N1)pdm, A(H3N2) and B was 87%, -9% , 74% (2011/12), and 74%, 39%, 73% (2012/13). VE was higher among hospitalized compared to non-hospitalized influenza A cases. Seventeen observational studies from Europe reporting subtype-specific VE among the elderly were identified for the respective seasons (all applying the test-negative design) and showed comparable subtype-specific VE estimates.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>According to our study, influenza vaccination provided moderate protection against laboratory-confirmed influenza A(H1N1)pdm and B in individuals aged 60+ but no or only little protection against A(H3N2). Higher VE among hospitalized cases might indicate higher protection against severe influenza disease. Based on the available data, the screening method allowed us to assess subtype-specific VE in hospitalized and non-hospitalized elderly persons. Since controlling for several important confounders was not possible, the applied method only provided crude VE estimates. However, given the precise VC-data and the large number of cases, the screening method provided results being in line with VE estimates from other observational studies in Europe that applied a different study design.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25887460</PMID>
<DateCompleted><Year>2015</Year>
<Month>12</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>15</Volume>
<PubDate><Year>2015</Year>
<Month>Mar</Month>
<Day>20</Day>
</PubDate>
</JournalIssue>
<Title>BMC infectious diseases</Title>
<ISOAbbreviation>BMC Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany.</ArticleTitle>
<Pagination><MedlinePgn>137</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-015-0882-3</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Elderly people are at increased risk for severe influenza illness and constitute therefore a major target-group for seasonal influenza vaccination in most industrialized countries. The aim of this study was to estimate influenza vaccine effectiveness (VE) among individuals aged 60+ years over three seasons and to assess if the screening method is a suitable tool to monitor influenza VE in this particular target-group in Germany.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We identified laboratory-confirmed influenza cases aged 60+ years through the national communicable disease reporting system for seasons 2010/11, 2011/12 and 2012/13. Vaccination coverage (VC) data were retrieved from a database of health insurance claims representing ~85% of the total German population. We applied the screening method to calculate influenza subtype-specific VE and compared our results with VE estimates from other observational studies in Europe.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 7,156 laboratory-confirmed influenza cases were included. VE against all influenza types ranged between 49% (95% confidence interval [CI]: 39-56) in 2011/12 and 80% (95% CI: 76-83%) in 2010/11. In 2010/11 subtype-specific VE against influenza A(H1N1)pdm and B was 76% and 84%, respectively. In the following seasons, VE against influenza A(H1N1)pdm, A(H3N2) and B was 87%, -9% , 74% (2011/12), and 74%, 39%, 73% (2012/13). VE was higher among hospitalized compared to non-hospitalized influenza A cases. Seventeen observational studies from Europe reporting subtype-specific VE among the elderly were identified for the respective seasons (all applying the test-negative design) and showed comparable subtype-specific VE estimates.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">According to our study, influenza vaccination provided moderate protection against laboratory-confirmed influenza A(H1N1)pdm and B in individuals aged 60+ but no or only little protection against A(H3N2). Higher VE among hospitalized cases might indicate higher protection against severe influenza disease. Based on the available data, the screening method allowed us to assess subtype-specific VE in hospitalized and non-hospitalized elderly persons. Since controlling for several important confounders was not possible, the applied method only provided crude VE estimates. However, given the precise VC-data and the large number of cases, the screening method provided results being in line with VE estimates from other observational studies in Europe that applied a different study design.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Remschmidt</LastName>
<ForeName>Cornelius</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Immunization Unit, Robert Koch Institute, Berlin, Germany. Remschmidtc@rki.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rieck</LastName>
<ForeName>Thorsten</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Immunization Unit, Robert Koch Institute, Berlin, Germany. RieckT@rki.de.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Charité - University Medicine Berlin, Berlin, Germany. RieckT@rki.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bödeker</LastName>
<ForeName>Birte</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Immunization Unit, Robert Koch Institute, Berlin, Germany. BoedekerB@rki.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wichmann</LastName>
<ForeName>Ole</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Immunization Unit, Robert Koch Institute, Berlin, Germany. WichmannO@rki.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>03</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>BMC Infect Dis</MedlineTA>
<NlmUniqueID>100968551</NlmUniqueID>
<ISSNLinking>1471-2334</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015166" MajorTopicYN="N">Monitoring, Immunologic</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>07</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>03</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>4</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>4</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25887460</ArticleId>
<ArticleId IdType="doi">10.1186/s12879-015-0882-3</ArticleId>
<ArticleId IdType="pii">10.1186/s12879-015-0882-3</ArticleId>
<ArticleId IdType="pmc">PMC4371628</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>PLoS One. 2014;9(6):e100497</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24945510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2014;10(2):476-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24192604</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2014;19(27):5-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25033051</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Jul 31;32(35):4443-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24962756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2014 Jul 1;210(1):126-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24446529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2014 Dec;14(12):1228-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25455990</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Rev. 1988;10:212-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3066628</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Epidemiol. 1993 Aug;22(4):742-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8225751</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 Apr;80(7):3675-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16537638</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Apr 20;25(16):3066-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17275144</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2007 Oct;13(10):1548-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18258005</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Epidemiol. 2008 Apr;61(4):344-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18313558</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2009;14(44). pii: 19388</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19941774</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2010;(2):CD004876</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20166072</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2010 May 6;15(18). pii: 19561</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20460094</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Oct 28;28(46):7381-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20851086</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dtsch Arztebl Int. 2010 Dec;107(48):845-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21173931</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2011;11:170</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21669006</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2011;6(11):e27622</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22110695</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):36-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22032844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Jan 5;30(2):195-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22100636</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Jan 5;30(2):109-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22100893</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 May 21;30(24):3595-602</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22472792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2012 Aug;55(3):332-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22539661</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Aug 24;30(39):5714-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22819720</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2012 Oct;55(7):951-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22843783</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2012;17(39). pii: 20281</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23041022</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013;18(5). pii: 20388</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23399423</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013;18(5). pii: 20389</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23399424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013;18(5). pii: 20390</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23399425</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013;18(6). pii: 20397</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23410258</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013;18(7):2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23449182</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Public Health. 2013;13:191</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23496887</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Apr 19;31(17):2165-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23499601</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Jun 26;31(30):3104-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23624093</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2013 Jul;57(2):167-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23532475</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Infect. 2013 Sep;141(9):1807-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23098364</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Aug 20;31(37):3766-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23810374</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2013;347:f5061</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23974637</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Recomm Rep. 2013 Sep 20;62(RR-07):1-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24048214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013;18(37). pii: 20585</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24079398</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2013;13:441</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24053661</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Dec 5;31(50):6030-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24095882</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Infect. 2014 Jan;142(1):126-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23591102</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2014 Feb;58(3):328-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24235266</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Feb 7;32(7):857-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24370711</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2014;19(6). pii: 20701</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24556348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Infect. 2013 Mar;141(3):620-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22691710</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2013 Nov;9(11):2453-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23811610</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2014 Aug;13(8):1039-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24946796</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>Berlin</li>
</region>
<settlement><li>Berlin</li>
</settlement>
</list>
<tree><country name="Allemagne"><region name="Berlin"><name sortKey="Remschmidt, Cornelius" sort="Remschmidt, Cornelius" uniqKey="Remschmidt C" first="Cornelius" last="Remschmidt">Cornelius Remschmidt</name>
</region>
<name sortKey="Bodeker, Birte" sort="Bodeker, Birte" uniqKey="Bodeker B" first="Birte" last="Bödeker">Birte Bödeker</name>
<name sortKey="Rieck, Thorsten" sort="Rieck, Thorsten" uniqKey="Rieck T" first="Thorsten" last="Rieck">Thorsten Rieck</name>
<name sortKey="Rieck, Thorsten" sort="Rieck, Thorsten" uniqKey="Rieck T" first="Thorsten" last="Rieck">Thorsten Rieck</name>
<name sortKey="Wichmann, Ole" sort="Wichmann, Ole" uniqKey="Wichmann O" first="Ole" last="Wichmann">Ole Wichmann</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000149 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000149 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeAllemagneV4
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:25887460
   |texte=   Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25887460" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeAllemagneV4

This area was generated with Dilib version V0.6.35.
Data generation: Mon Aug 10 17:53:30 2020. Site generation: Sat Mar 27 17:40:37 2021

	Serveur d'exploration sur la grippe en Allemagne
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la grippe en Allemagne

Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany.

Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki